Cargando…

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

BACKGROUND: For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis. METHODS: A search was conducted on EMBASE and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Liuting, Jiang, Xiaoyue, Yan, Han, Li, Yingying, Zhen, Hongchao, Chang, Bingmei, Kariminia, Seyed, Li, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879920/ https://www.ncbi.nlm.nih.gov/pubmed/29609559 http://dx.doi.org/10.1186/s12876-018-0772-4

Ejemplares similares

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
por: Satoh, Taroh, et al.
Publicado: (2014)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
por: Jung, Joo Young, et al.
Publicado: (2016)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
por: Zhang, Hangyu, et al.
Publicado: (2023)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
por: Carter, Kevin A, et al.
Publicado: (2016)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
por: Ramaswamy, Anant, et al.
Publicado: (2018)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
por: Jeung, H-C, et al.
Publicado: (2006)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
por: Ogawa, Kohei, et al.
Publicado: (2012)

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
por: Baek, Jin Ho, et al.
Publicado: (2005)

Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer
por: RINO, YASUSHI, et al.
Publicado: (2013)

Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
por: Dai, Xichao, et al.
Publicado: (2023)

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
por: Zheng, Yi, et al.
Publicado: (2018)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
por: Aktas, Gokmen, et al.
Publicado: (2016)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body
por: Idili, Andrea, et al.
Publicado: (2019)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Phase II Study of Irinotecan Plus Panitumumab as Second‐Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
por: Yoon, Harry, et al.
Publicado: (2018)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
por: Georgoulias, V, et al.
Publicado: (2004)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
por: Zhang, Xiaowei, et al.
Publicado: (2022)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
por: Feng, Haiyang, et al.
Publicado: (2014)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Irinotecan-Induced Steatohepatitis: Current Insights
por: Han, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vk6f3e9op06l5s4mlqk5akons1